Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Gliosarcoma 1Colorectal Neoplasms 1

Interventions

Cetuximab 44Oxaliplatin 39Irinotecan 38Fluorouracil 36Capecitabine 36pembrolizumab 35Leucovorin 35Bevacizumab 35Nivolumab 21Gemcitabine 17regorafenib 13Panitumumab 12IFL protocol 12Folfox protocol 12Cyclophosphamide 12Pemetrexed 11Cisplatin 11tislelizumab 9Paclitaxel 9HMPL-013 9Carboplatin 9130-nm albumin-bound paclitaxel 8durvalumab 7Specimen Handling 7Docetaxel 7trametinib 6Trifluridine 6Ipilimumab 6Drug Therapy 6trifluridine tipiracil drug combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Neoplasms × NVP-BKM120 × Clear all
NCT01591421 2023-08-04

P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

Canadian Cancer Trials Group

Phase 1/2 Completed
22 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡